IRIDEX Launches Revised MicroPulse P3® Device for Glaucoma
February 26 2020 - 04:03PM
IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative
ophthalmic laser-based medical products for the treatment of
glaucoma and retinal diseases, announced today the introduction of
the second generation of the MicroPulse P3® Device, which has been
redesigned to deliver greater stability, visualization, coupling,
and fit.
“The revised MicroPulse P3 Device is intuitive
and easy to use. The design delivers energy in a much more
consistent fashion and allows for very stable contact on the
sclera,” said Dr. Brian A. Francis, Associate Professor of
Ophthalmology at the Doheny Eye Institute, Keck School of Medicine,
University of Southern California. “This device offers myself and
my patients a treatment paradigm which can be introduced prior to,
in conjunction with and following all other glaucoma treatment
options, making it a very versatile tool in my practice.”
The new MicroPulse P3 Device features a number
of design improvements:
- Recessed fiber tip with added fluid channel to enable
consistent fiber immersion in fluid during treatment to improve
light coupling to the tissue.
- Concave “scleral-matching” footplate plate to improve
stability.
- “Limbal-matching” footplate curvature added to better identify
the orientation and placement of the device.
- Reduced footplate size for easier placement in eyes.
- Elongated stem to improve visualization of the treatment
area.
“The launch of our revised MicroPulse P3 Device
represents an important step forward in simplifying our unique
non-incisional glaucoma therapy. We are pleased with the initial
physician users’ positive response to the product improvements,”
said David Bruce, CEO of IRIDEX. “We anticipate these ease of use
improvements will lead to greater physician confidence and
adoption.”
The MicroPulse P3 Device is used by physicians
to perform MicroPulse® Transscleral Laser Therapy (TLT), which is a
non-incisional, laser-energy procedure delivering substantial
reduction in intraocular pressure suitable for a broad range of
glaucoma patients. More than 120,000 patients have been treated in
over 60 countries with the original version of the MicroPulse P3
Device.
At the American Glaucoma Society annual meeting
taking place in Washington, DC on February 27-29, 2020, IRIDEX will
host “Meet the MicroPulse TLT Experts” sessions Thursday and
Friday, where attendees can engage in physician discussions to
learn how experts, including Dr. Brian Francis, are utilizing
MicroPulse TLT and the revised MicroPulse P3 Device. More details
and specific times can be found at www.iridex.com/ags.
In addition, MicroPulse TLT will be
discussed in several data presentations at the meeting. Noteworthy
data includes:
- PO001 - Outcomes of IRIDEX MicroPulse P3 (MP3) with
Higher-Than-Usual Settings for the Management of Elevated Eye
Pressure; Speaker- Nandita Anand
- PO007 - Comparison of Clinical Outcomes After MicroPulse and
Continuous Wave Transscleral Cyclophotocoagulation; Speaker- Monica
Ertel
- PO010 - The Effect of Iris Color on Outcomes of MicroPulse
Cyclophotocoagulation (mTSCPC) in Adult Glaucoma Patients at One
Year; Speaker- Sara Hooshmand
- PO019 - Efficacy and Safety of MicroPulse Transscleral
Cyclophotocoagulation (M-TSCPC) in Uncontrolled Mild to Severe
Glaucoma: A Single Center Canadian Study; Speaker- Rodolpho
Matsumoto
The revised MicroPulse P3 Device is now
commercially available in the U.S. The device is projected to be
available outside the U.S over the next few months.
About IRIDEXIRIDEX is a
worldwide leader in developing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation
for the ophthalmology market. The Company’s proprietary MicroPulse®
technology delivers a differentiated treatment that provides safe,
effective, and proven treatment for targeted sight-threatening eye
conditions. IRIDEX’s current product line is used for the
treatment of glaucoma, diabetic macular edema (DME) and other
retinal diseases. IRIDEX products are sold in the United
States and Germany through a direct sales force and in more than
100 countries through a network of independent distributors. For
more information, visit www.iridex.com/MicroPulseP3.
Safe Harbor Statement This
announcement contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Act of 1934, as amended, including
those statements concerning adoption of the Company's products
and the timing of availability outside the U.S. These statements
are not guarantees of future performance and actual results may
differ materially from those described in these forward-looking
statements as a result of a number of factors. Please see a
detailed description of these and other risks contained in our
Annual Report on Form 10-K for the fiscal year ended December
29, 2018, and Quarterly Reports on Form 10-Q for subsequent fiscal
quarters, each of which was filed with the Securities and
Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date and will not be updated.
Investor Relations Contact Leigh Salvo (415)
937-5404 investors@iridex.com
Media Contact Jamie Hall Pascale
Communications, LLC. (724) 417-0167 pr@iridex.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Feb 2024 to Mar 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Mar 2023 to Mar 2024